Business

Altria CEO says ‘responsibility needs to be at the heart’ of its FDA-regulated nicotine business. It’s part of why it sued the regulator

What we want is more rapid authorization, so that consumers have product choices that they can choose from.” The regulatory landscape of nicotine is similar in some ways to how cannabis is being introduced and regulated in U.S.

✦ Extractive summary — built from the sources' own reporting•From 1 source•2 min read•Updated November 17, 2026, 7:37 PM UTC
Key points
  • Through the Premarket Tobacco Product Application (PMTA), the FDA is legally required to review new tobacco products before they reach market and decide if the product provides an overall public health benefit within 180 days of submitting an application.
  • Reiterating what was in the lawsuit, he said what should take the FDA six months to review was taking six years in some cases, allowing illegal products, particularly from China, from not just taking market share, but also skirting standards Mancuso believes the FDA should keep in place to protect the safety of the consumer.
  • As Big Tobacco companies pivot away from combustible products to less harmful nicotine alternatives, they’re finding new challenges in their relationships with regulators.

Altria claims the FDA has failed to meet that deadline, and that the regulator’s red tape and bureaucracy stalled newer On!

Mancuso explained that Altria sued the FDA because it needed enforcement against illicit products.

Additional details
  • “When you think about what’s maybe getting in the way, there’s a couple of factors: One is just the misperception that nicotine is what causes harm from tobacco use.
  • District Judge James Wesley Hendrix of the Northern District of Texas granted a joint request from the FDA and the plaintiffs to pause litigation.
  • The Marlboro-maker announced its Moving Beyond Smoking initiative in 2023 as more consumers move away from cigarettes, putting a renewed focus on smoke-free alternatives to cigarettes such as NJOY vapes and On!
  • The FDA said it would consider revisions to the PMTA and consider new rules as the market continues to change, and last month, U.S.
  • “You can call us the underdog in the pouch category today, but our intention is to lead the pouch category over the long term,” Mancuso told Fortune Executive Editorial Director Diane Brady.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet